바이오인

Epigenetic Biomarkers and Clinical Trials

This report presents a snapshot of the epigenetic landscape as it is today.

The of this GEN Market & Tech Analysis report is to present some of our recent industry tracking of the epigenetics clinical trials and biomarker signatures space.

Highlights of this report:

■ The epigenetics space represents a rich source of biomarkers and potential therapeutics since the target of action (chromatin) is highly proximal to the site of gene expression.

■ DNA is highly stable ex vivo and offers an excellent ing material for the development of prognostic or predictive biomarker-based tests (potential for epigenetics-based clinical diagnostics development).

■ Clinical trials in the epigenetics space are 50% ed on various cancer classes-indeed this represents the role of cancer as key driver of the epigenetic field, and the current FDA-approved epigenetics-based drugs target various cancer classes.

■ Even though epigenetics is an “amorphous space” we believe that, from a diagnostics and therapeutics perspective, we cannot discount its potential given strong drivers in its favor.

■ Beyond cancer, another area where epigenetics modifications are gaining increasing interest are in the CNS, where epigenetics s may underlie learning, memory, etc.

.....(계속)

☞ 자세한 내용은 내용바로가기의 첨부파일을 이용하시기 바랍니다.